Description
Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:
- why certain trials have failed whereas others have succeeded,
- what we have learned about the connection between overall survival and progression-free survival as endpoints, and
- how the systemic therapy of HCC has evolved.
Faculty
- Prof. Peter Galle (Moderator)
- Prof. Bruno Sangro (Faculty)
- Dr Anna Saborowski (Faculty)
- Prof. Arndt Vogel (Faculty)
Related episodes
- S2E15 – JHEP Live – The best animal model for HCC — lost in translation
- Special Edition: Highlights of the Liver Cancer Summit 2022
- Policy Dialogues Episode 3: Liver Cancer: The risk of ignorance
ℹ️ Please click here to access the podcast version of this EASL Studio episode.